Technology area: Biotechnology & Pharmaceuticals
20 pending office actions • 15 clients • 18 examiners • 12 art units • 0 of 20 (0%) have an AI response strategy ready
Knowles Intellectual Property Strategies, LLC works in Biotechnology & Pharmaceuticals and has 794 career applications. Its current docket contains 18 pending office actions, showing active prosecution within a developed application record.
The resolved allowance rate is 78.24%, and allowed matters required an average of 2.31 office actions. These measures provide a combined view of historical allowance outcomes and the amount of examination activity typically associated with matters that reached allowance.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (5%) |
| §103 only | 7 (35%) |
| §102 only | 1 (5%) |
| Double-patenting only | 2 (10%) |
| Double-patenting + other | 6 (30%) |
| Multi-statute (no §101) | 2 (10%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 2 | 47.3% | +27.2% |
| HOWELL, THEODORE R | 2 | 66.9% | +25.1% |
| LIU, TRACY | 1 | 54.5% | +26.9% |
| HELLMAN, KRISTINA M | 1 | 65.1% | +55.5% |
| LIEB, JEANETTE M | 1 | 79.8% | +17.4% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
| LANKFORD JR, LEON B | 1 | 70.0% | +31.5% |
| MCINTOSH III, TRAVISS C | 1 | 73.3% | +14.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18769136 | NASAL HYGIENE COMPOSITIONS, ANTIMICROBIAL TREATMENTS, DEVICES, AND ARTICLES FOR DELIVERY OF SAME TO THE NOSE, TRACHEA AND MAIN BRONCHI | HAGHIGHATIAN, MINA | — |
| 18586086 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | CHO, DAVID H | — |
| 17983098 | TREATMENT OF METABOLIC DISORDERS THROUGH THE TARGETING OF A NOVEL CIRCULATING HORMONE COMPLEX | GERIDO, DWAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18195296 | Method for Reducing Ototoxicity in Pediatric Patients Receiving Plantinum-Based Chemotherapy | HOWELL, THEODORE R | 78d overdue |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CRAIGO, BAHAR ALAWI | 7d |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | DABKOWSKI, ERINNE R | 83d |
| 19427735 | QUATERNARY AMMONIUM SILANE AQUEOUS HYDROGEL FORMULATIONS | LIU, TRACY | — |
| 19329410 | CELL-PENETRATING PEPTIDE COMPOUNDS | HELLMAN, KRISTINA M | — |
| 19329431 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | LIEB, JEANETTE M | — |
| 18957362 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | KOSAR, ANDREW D | — |
| 18917928 | METHOD OF TREATING DIABETIC MACULAR EDEMA | HUANG, GIGI GEORGIANA | — |
| Art Unit | Apps |
|---|---|
| 1654 | 3 |
| 1693 | 3 |
| 1628 | 3 |
| 1625 | 2 |
| 1699 | 2 |
| 1614 | 1 |
| 1613 | 1 |
| 1657 | 1 |
| 1616 | 1 |
| 1624 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19427735 | QUATERNARY AMMONIUM SILANE AQUEOUS HYDROGEL FORMULATIONS | Topikos Scientific, Inc. | LIU, TRACY | 1614 | §103 | Final Rejection | — | Pending | Dec 19, 2025 |
| 19329410 | CELL-PENETRATING PEPTIDE COMPOUNDS | Ohio State Innovation Foundation | HELLMAN, KRISTINA M | 1654 | §112DP | Non-Final OA | — | Pending | Sep 15, 2025 |
| 19329431 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | Ohio State Innovation Foundation | LIEB, JEANETTE M | 1654 | §103§112DP | Non-Final OA | — | Pending | Sep 15, 2025 |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | Ohio State Innovation Foundation | DABKOWSKI, ERINNE R | 1654 | §103Other | Final Rejection | 83d | Pending | Sep 15, 2025 |
| 18957362 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | Atea Pharmaceuticals, Inc. | KOSAR, ANDREW D | 1625 | §103 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18917928 | METHOD OF TREATING DIABETIC MACULAR EDEMA | Oculis Operations Sàrl | HUANG, GIGI GEORGIANA | 1613 | §103DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18892143 | SYSTEMS AND METHODS FOR OPTIMIZED PATIENT SPECIFIC TISSUE ENGINEERING VASCULAR GRAFTS | Research Institute AT Nationwide Children'S Hospital | LANKFORD JR, LEON B | 1657 | DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18828972 | Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | Atea Pharmaceuticals, Inc. | MCINTOSH III, TRAVISS C | 1693 | DP | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18792377 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Oculis Operations Sàrl | ISMAIL, REHANA | 1625 | §103DP | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18769136 | NASAL HYGIENE COMPOSITIONS, ANTIMICROBIAL TREATMENTS, DEVICES, AND ARTICLES FOR DELIVERY OF SAME TO THE NOSE, TRACHEA AND MAIN BRONCHI | Sensory Cloud, Inc. | HAGHIGHATIAN, MINA | 1616 | §103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18749420 | SYNTHESIS OF PHOSPHATE DERIVATIVES | Nucana PLC | BERRY, LAYLA D | 1693 | §103 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18653750 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. | MCDOWELL, BRIAN E | 1624 | §102 | Non-Final OA | — | Pending | May 02, 2024 |
| 18592037 | 2'-CHLORO-2'-FLUORO-N2-AMINO-N6-METHYLAMINO PURINE NUCLEOTIDES FOR FLAVIVIRUS TREATMENT | Atea Pharmaceuticals, Inc. | CRAIGO, BAHAR ALAWI | 1699 | §103DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18586086 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | Avilar Therapeutics, Inc. | CHO, DAVID H | 1693 | §103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18375162 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals Inc. | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | 3d overdue | Pending | Sep 29, 2023 |
| 18236836 | METHOD FOR REDUCING OTOTOXICITY IN PEDIATRIC PATIENTS RECEIVING PLATINUM-BASED CHEMOTHERAPY | The United States Department of Veterans Affairs | HOWELL, THEODORE R | 1628 | §102§103DP | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | Pharmacosmos Holding A/S | CRAIGO, BAHAR ALAWI | 1699 | Other | Non-Final OA | 7d | Pending | Aug 07, 2023 |
| 18210991 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | Hoffmann-La Roche, Inc. | LEE, CHIHYI NMN | 1628 | §103 | Final Rejection | 32d overdue | Pending | Jun 16, 2023 |
| 18195296 | Method for Reducing Ototoxicity in Pediatric Patients Receiving Plantinum-Based Chemotherapy | The United States Department of Veterans Affairs | HOWELL, THEODORE R | 1628 | §103 | Final Rejection | 78d overdue | Pending | May 09, 2023 |
| 17983098 | TREATMENT OF METABOLIC DISORDERS THROUGH THE TARGETING OF A NOVEL CIRCULATING HORMONE COMPLEX | The President and Fellows of Harvard College | GERIDO, DWAN A | 1797 | §101§112 | Final Rejection | — | Pending | Nov 08, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial78.2% of resolved applications prosecuted by Knowles Intellectual Property Strategies, LLC were allowed, across 794 applications in USPTO records.
2.31 office actions per allowed application on average.
20 pending office actions as of October 2026, for 15 clients, before 18 examiners in 12 art units.
